BioLineRx

Published today in PharmaVoice: We’re excited to share the powerful journey BioLineRx has taken since its founding, from incubator to publicly-traded commercial company. Enjoy this look back and a brief view of our vision for the future. Read the full story: https://lnkd.in/d7HajnWN

Join BioLineRx ($BLRX) for the final episode in the “Power of Persistence” BioPharma Dive podcast series. This week, BioLineRx’s CEO Phil Serlin discusses how to navigate the delicate balance between launching a company’s first commercial product while also nurturing a robust pipeline and forming collaborations to accelerate growth and maximize impact. https://lnkd.in/g8hVzZ6j

Just in for biotech podcast listeners! Episode 2 of the three-part BioPharma Dive Power of Persistence podcast series just dropped. In this episode, BioLineRx’s president Holly May discusses the crucial role of building and optimizing the right team at the right moment, strategies for hiring and nurturing top talent, and creating a dynamic team she describes as "a bunch of Swiss army knives". Listen here: https://bit.ly/4en75oA

We're excited to announce the launch of the three-part BioPharma Dive podcast series titled "The Power of Persistence: From Biotech Incubator to Product Launch.” The series focuses on BioLineRx’s journey to a commercial company. In Episode 1, Phil Serlin, CEO of BioLineRx, shares the company's vivid journey from entrepreneurial incubator to strategic, focused commercial company. A must listen for early-stage biotech company builders. Enjoy and join us soon for Episode 2, on June 12th. https://lnkd.in/g8hVzZ6j

BioLineRx is excited to announce a multi-center Phase 1 clinical trial sponsored by St. Jude Children's Research Hospital to evaluate single agent motixafortide for the mobilization of CD34+ hematopoietic stem cells used in the development of gene therapies for patients with sickle cell disease. Read more: https://bit.ly/3wYmHy5

BiolineRx ($BLRX) is excited to announce the acceptance of an abstract and poster session at #ASCO2024. Dr. Gulam Manji MD, PhD, will be presenting on the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial in first-line pancreatic cancer. Read More: https://lnkd.in/etsDHeX2

May is National #Oncology Nursing Month! Join us ($BLRX) this month in our appreciation for the role oncology #nurses play in patient care and their powerful impact. We honor these nurses for their passion, dedication, and commitment to helping patients with cancer.

Every biotech has an interesting backstory. BioLineRx’s story has been about being “the little engine that could,” with a team that believes in itself and where we are heading for patients. So proud of our journey.

Join us BioLineRx ($BLRX) this May in recognition of National #Cancer Research Month to highlight the importance of lifesaving research to help millions of people around the world affected by cancer. We hope that effective treatments will be continually developed to fight this devastating disease through ongoing research and hard work. 

Visit our #ISPOR ‘24 poster “The Institutional Level Impact of Additional Apheresis Days for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation on Costs and Healthcare Resource Utilization” ISPOR—The Professional Society for Health Economics and Outcomes Research presented by Jeffrey Skaar (Trinity Life Sciences) and Jennifer L. Lessor, MPH